Phase II trial of Rituxan [rituximab] plus FavId (tumor-specific idiotype-KLH) [mitumprotimut T] and GM-CSF [granulocyte-macrophage colony-stimulating factors] immunotherapy in patients with grade 1 or 2 follicular B-cell lymphoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2011
At a glance
- Drugs Mitumprotimut T; Rituximab; Sargramostim
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 06 Dec 2007 Four-year follow-up results to be reported at ASH 2007.
- 10 Nov 2005 New trial record.